Daiichi Sankyo's Tumor Drug Meets Primary Endpoint in Late-Stage Study By Sam | October 30, 2017 Daiichi Sankyo announced that its Phase III ENLIVEN trial of pexidartinib met its primary endpoint. Source: BioSpace Posted in BioPharma